Onward Therapeutics is focused on the development of new drugs to treat hematological and solid tumors.
Route de la Corniche 4
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy
Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
Life sciences entrepreneurs at Biopôle never stop innovating. Enter your e-mail and get monthly updates delivered to your inbox